Interview with Dr. Andreas Meudt, Head of Exclusive Synthesis, Evonik
At least seven drug products utilizing continuous manufacturing processes have been approved by the FDA to-date, with many others in clinical development. However, when it comes to APIs and advanced intermediates, there are few pharmaceutical companies that have successfully utilized continuous manufacturing for more than a single process step. In addition, very few have been able to scale-up beyond the kilogram range under cGMP conditions. In this interview with Dr. Andreas Meudt, Head of Exclusive Synthesis for Evonik, the challenges and opportunities for the use of continuous manufacturing for APIs and intermediates are reviewed.